All Articles

N-able partners with Trigent to launch a key India R&D hub, signaling a strategic shift to harness local AI talent for next-gen global cyber defense.

FlightHub is expanding from flights to a full-service travel platform. But can its new hotel booking service truly challenge giants like Expedia and Booking.com?

With its stock lagging despite strong sales, Insulet brings on a proven value-creator. Can the 'Mazelsky Playbook' accelerate growth and fend off rivals?

UpDoc just secured the first FDA clearance for a patient-facing clinical AI. This isn't just another app; it's a new paradigm for healthcare delivery.

Avianca is paying more to borrow for longer. We analyze the $650M bond deal that trades higher interest costs for a clear path to execute its growth strategy.

Aidoc's 'First Read' AI has earned a coveted FDA Breakthrough designation, promising to ease radiologist workload. But can an algorithm be trusted with your health?

The sudden death of veteran counsel E. Forrest Jones Jr. leaves a void at Ramaco Resources, testing its leadership amid a high-stakes pivot to critical minerals.

Beyond the press release, MegaGen's investment in BIOLASE is a strategic masterclass in post-acquisition revival, aiming to dominate the dental tech market.

The iconic bakery brand is making a strategic pivot into the massive on-the-go snacking market with its new pretzel bites, a move that redefines convenience.

The lender's 10% yield attracts income investors, but a tight payout ratio and market shifts raise questions about its long-term sustainability.

Beyond the music, the 2026 CCMA Awards reveal a powerful synergy between city branding, artist entrepreneurship, and integrated media strategy. A new blueprint?

A new contract goes beyond equipment, revealing a strategic blueprint for Angola's energy sector, local growth, and the future of ultra-deepwater operations.

Lightbridge Corp. hits a critical milestone at Idaho National Lab, moving its advanced nuclear fuel from theory to tangible data. What does this signal mean?

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

Verano's upcoming Q2 report is a key indicator for the cannabis sector. We look at the strategic moves, from stock splits to rescheduling, setting the stage.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

China's data center giant GDS secures a massive war chest and reshuffles its board, signaling an aggressive push to dominate the AI infrastructure boom.

By offering free Starlink Wi-Fi, Alaska Air Group isn't just upgrading a service; it's weaponizing connectivity to win loyalty and challenge rivals.